Opportunity Information: Apply for PAR 14 248
Apply for PAR 14 248
- The National Institutes of Health in the education health income security and social services sector is offering a public funding opportunity titled "Basic Research on HIV Persistence (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.242 Mental Health Research Grants 93.279 Drug Abuse and Addiction Research Programs 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Jun 4, 2014 and posted on Jun 4, 2014.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- The number of recipients for this funding is limited to 8 candidate(s).
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Public and State controlled institutions of higher education Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments State governments City or township governments Independent school districts Native American tribal governments (Federally recognized) County governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Basic Research on HIV Persistence (R21)" (Funding Opportunity Number PAR-14-248) supports exploratory, hypothesis-driven basic research aimed at explaining why HIV-1 can continue to persist in people who are taking highly active antiretroviral therapy (HAART). Even when treatment suppresses the virus to levels that are hard to detect, HIV can remain in the body in long-lived reservoirs and rebound if therapy stops. This FOA is focused on generating new biological insight into that persistence problem and on encouraging creative early-stage work that could reshape how the field thinks about long-term remission or cure.
The mechanism is an Exploratory/Developmental Research Grant (R21), which is typically used for high-impact ideas that are still in relatively early phases and may not yet have extensive preliminary data. The announcement explicitly welcomes projects that involve considerable risk, as long as the potential payoff is meaningful. In practice, that means the FOA is well-suited for teams proposing unconventional hypotheses about HIV latency and reservoir maintenance, novel laboratory or computational approaches, or innovative experimental systems that could open up new directions for later, larger studies. A central theme is helping the field move toward strategies that could achieve either durable remission without ongoing treatment (sometimes referred to as a functional cure) or complete eradication of residual virus (a sterilizing cure), by first strengthening the basic science foundation needed to design those strategies.
A major emphasis is on developing new ideas and approaches to studying HIV-1 persistence, including the creation or improvement of models and assays. Model development can include in vitro systems, animal models, or other experimental platforms that better replicate the biology of HIV reservoirs during suppressive therapy. Assay development can include more sensitive or more informative methods for detecting and characterizing residual virus, measuring the size and activity of latent reservoirs, or tracking viral rebound dynamics. The intent is that these foundational tools and concepts will directly inform future therapeutic research, even if the R21 project itself is not a clinical trial or a near-term product development effort.
From an administrative and funding standpoint, this is a discretionary grant program run by the National Institutes of Health. The FOA projected approximately 8 awards with an estimated total funding amount of about $2,000,000. The award ceiling listed is $200,000, consistent with the smaller, exploratory nature of the R21 mechanism. There is no cost-sharing or matching requirement, which lowers barriers for applicants who may not have non-federal funds available to support the work.
Eligibility is broad and spans many organization types, reflecting NIH-wide participation in HIV research. Eligible applicants include public and private institutions of higher education, nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status), for-profit organizations (including small businesses), and various government entities at the state, county, city, township, and special district levels. The FOA also lists Tribal governments and Tribal organizations, public housing authorities/Indian housing authorities, independent school districts, and other categories commonly eligible for NIH grants. Additional eligible applicants explicitly include historically underrepresented and mission-focused institutions and organizations such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander serving institutions (AANAPISIs), as well as faith-based and community-based organizations where appropriate. Importantly, the eligibility list also includes non-U.S. entities (foreign organizations) and regional organizations, as well as U.S. territories or possessions, which signals that NIH was open to strong proposals regardless of geography, provided all NIH policy requirements were met.
The announcement was posted on June 4, 2014, with the original and current closing date shown as January 7, 2017, and an archive date of February 7, 2017, meaning it is no longer open for new submissions under that specific posting. For reference and full details, the FOA points to the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PAR-14-248.html, and includes the NIH Office of Extramural Research (OER) webmaster contacts for technical access issues.
Overall, PAR-14-248 was designed to push the science of HIV persistence forward by funding bold, early-stage basic research and enabling the development of better experimental models and measurement tools. The long-term goal behind that basic research investment is to make it possible to rationally design and test therapeutic strategies that could ultimately lead to sustained remission without therapy or a complete cure by eliminating residual virus.
FAQs: NIH "Basic Research on HIV Persistence (R21)" (PAR-14-248)
What is the title and funding opportunity number for this grant?
The funding opportunity is titled "Basic Research on HIV Persistence (R21)" and the Funding Opportunity Number (FON) is PAR-14-248.
What is the main purpose of PAR-14-248?
This FOA supports exploratory, hypothesis-driven basic research aimed at explaining why HIV-1 can persist in people taking highly active antiretroviral therapy (HAART), even when treatment suppresses virus levels to hard-to-detect amounts. The focus is on generating new biological insight into HIV persistence and encouraging creative early-stage work that could reshape how the field approaches long-term remission or cure.
What problem is the FOA trying to address about HIV under HAART?
Even when HAART suppresses HIV to levels that are difficult to detect, HIV can remain in the body in long-lived reservoirs. If therapy stops, the virus can rebound. The FOA targets the underlying biology of this persistence and rebound risk.
What NIH grant mechanism does this opportunity use?
The mechanism is the Exploratory/Developmental Research Grant (R21), which is typically used to support high-impact ideas that are still in relatively early phases.
Is preliminary data required or expected for an R21 under this FOA?
The FOA describes the R21 mechanism as appropriate for early-phase, high-impact concepts that may not yet have extensive preliminary data. It explicitly welcomes projects involving considerable risk when the potential payoff is meaningful.
What kinds of projects are considered a good fit for this FOA?
The FOA is well-suited for unconventional hypotheses about HIV latency and reservoir maintenance, novel laboratory or computational approaches, and innovative experimental systems that could open new directions for later, larger studies. The central theme is generating foundational biological insight into HIV persistence during suppressive therapy.
Does this FOA focus on basic research or clinical trials?
The FOA is focused on basic research. It emphasizes foundational tools and concepts that can inform future therapeutic research, even if the R21 project itself is not a clinical trial or a near-term product development effort.
How does this FOA relate to HIV cure concepts like remission or eradication?
The FOA aims to strengthen the basic science foundation needed to design strategies that could achieve either durable remission without ongoing treatment (often called a functional cure) or complete eradication of residual virus (a sterilizing cure). The immediate goal is biological insight and improved research approaches, with long-term relevance to cure strategies.
What major scientific areas are emphasized in the FOA?
A major emphasis is on developing new ideas and approaches to studying HIV-1 persistence, including the creation or improvement of models and assays to better replicate, detect, and characterize HIV reservoirs and residual virus during suppressive therapy.
What does "model development" mean in the context of this FOA?
Model development can include in vitro systems, animal models, or other experimental platforms designed to better replicate the biology of HIV reservoirs during suppressive therapy.
What does "assay development" mean in this FOA?
Assay development can include more sensitive or more informative methods for detecting and characterizing residual virus, measuring the size and activity of latent reservoirs, or tracking viral rebound dynamics.
Approximately how many awards were expected under PAR-14-248?
The FOA projected approximately 8 awards.
What was the estimated total funding amount for this FOA?
The FOA estimated a total funding amount of about $2,000,000.
What is the award ceiling for this opportunity?
The award ceiling listed is $200,000, which aligns with the smaller, exploratory nature of the R21 mechanism as described in the opportunity summary.
Is cost-sharing or matching required?
No. The FOA states there is no cost-sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include public and private institutions of higher education, nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status), for-profit organizations (including small businesses), and various government entities (state, county, city, township, and special district). The FOA also lists Tribal governments and Tribal organizations, public housing authorities/Indian housing authorities, independent school districts, and other commonly eligible NIH applicant categories.
Are mission-focused and historically underrepresented institutions included in eligibility?
Yes. The FOA explicitly includes institutions and organizations such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander serving institutions (AANAPISIs). It also mentions faith-based and community-based organizations where appropriate.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The eligibility list includes non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions, indicating the NIH was open to strong proposals regardless of geography, provided NIH policy requirements were met.
When was the FOA posted?
The announcement was posted on June 4, 2014.
What was the closing date for submissions under this posting?
The original and current closing date shown is January 7, 2017.
Is this opportunity still open?
No. The FOA shows an archive date of February 7, 2017, indicating it is no longer open for new submissions under that specific posting.
Where can applicants find the official FOA details?
The FOA points to the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PAR-14-248.html.
Who should be contacted for technical access issues related to the FOA page?
The FOA includes NIH Office of Extramural Research (OER) webmaster contacts for technical access issues.
What is the broader long-term goal behind this FOA?
The broader goal is to push the science of HIV persistence forward by funding bold, early-stage basic research and enabling better experimental models and measurement tools. Over time, this basic research investment is intended to make it possible to rationally design and test therapeutic strategies that could lead to sustained remission without therapy or a complete cure by eliminating residual virus.
Browse more opportunities from the same category: Education Health Income Security and Social Services
Next opportunity: Basic Research on HIV Persistence (R01)
Previous opportunity: Pacific Coast Joint Venture Administration
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 248
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 248) also looked into and applied for these:
| Funding Opportunity |
|---|
| Basic Research on HIV Persistence (R01) Apply for PAR 14 247 Funding Number: PAR 14 247 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of in vivo Chemical Probes (R01) Apply for PAR 14 279 Funding Number: PAR 14 279 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| U.S. China Program for Research Toward a Cure for HIV/AIDS (R01) Apply for RFA AI 14 057 Funding Number: RFA AI 14 057 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $1,350,000 |
| High Throughput Screening (HTS) to Discover Chemical Probes (R21) Apply for PAR 14 283 Funding Number: PAR 14 283 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| Blueprint Neurotherapeutics Network (BPN) Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) Apply for PAR 14 292 Funding Number: PAR 14 292 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Blueprint Neurotherapeutics Network (BPN) Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3) Apply for PAR 14 293 Funding Number: PAR 14 293 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition Research Training for Career Development of Junior Faculty in Medical Education Partnership Initiative (MEPI) Institutions (D43) Apply for RFA TW 14 003 Funding Number: RFA TW 14 003 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $600,000 |
| Physical Sciences Oncology Network (PS ON) Physical Sciences Oncology Projects (PS OP) (U01) Apply for PAR 15 021 Funding Number: PAR 15 021 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $500,000 |
| Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC) (U01) Apply for RFA HD 15 029 Funding Number: RFA HD 15 029 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $17,975,000 |
| BRAIN Initiative New Technologies and Novel Approaches for Large Scale Recording and Modulation in the Nervous System (U01) Apply for RFA NS 15 003 Funding Number: RFA NS 15 003 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01) Apply for RFA NS 15 004 Funding Number: RFA NS 15 004 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Integrated Approaches to Understanding Circuit Function in the Nervous System (U01) Apply for RFA NS 15 005 Funding Number: RFA NS 15 005 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Planning for Next Generation Human Brain Imaging (R24) Apply for RFA MH 15 200 Funding Number: RFA MH 15 200 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $300,000 |
| BRAIN Initiative Development and Validation of Novel Tools to Analyze Cell Specific and Circuit Specific Processes in the Brain (U01) Apply for RFA MH 15 225 Funding Number: RFA MH 15 225 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| Empirical Research on Ethical Issues Related to Central IRBs and Consent for Research Using Clinical Records and Data (R01) Apply for RFA OD 15 002 Funding Number: RFA OD 15 002 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Short Courses in Computational Neuroscience (R25) Apply for RFA MH 15 215 Funding Number: RFA MH 15 215 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $200,000 |
| BRAIN Initiative Short Courses in Research Tools and Methods (R25) Apply for RFA MH 15 220 Funding Number: RFA MH 15 220 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $250,000 |
| Predictive Multiscale Models for Biomedical, Biological, Behavioral, Environmental and Clinical Research (U01) Apply for PAR 15 085 Funding Number: PAR 15 085 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Next Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH2/UH3) Apply for RFA NS 15 006 Funding Number: RFA NS 15 006 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Clinical Studies to Advance Next Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3) Apply for RFA NS 15 008 Funding Number: RFA NS 15 008 Agency: National Institutes of Health Category: Education Health Income Security and Social Services Funding Amount: $1,500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 248", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.